Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2012; 7(12): e51697.
Published online 2012 December 17. doi:  10.1371/journal.pone.0051697
PMCID: PMC3524114

8-Oxoguanine DNA Glycosylase (OGG1) Deficiency Increases Susceptibility to Obesity and Metabolic Dysfunction

Ferenc Gallyas, Editor


Oxidative damage to DNA is mainly repaired via base excision repair, a pathway that is catalyzed by DNA glycosylases such as 8-oxoguanine DNA glycosylase (OGG1). While OGG1 has been implicated in maintaining genomic integrity and preventing tumorigenesis, we report a novel role for OGG1 in altering cellular and whole body energy homeostasis. OGG1-deficient (Ogg1−/−) mice have increased adiposity and hepatic steatosis following exposure to a high-fat diet (HFD), compared to wild-type (WT) animals. Ogg1−/− animals also have higher plasma insulin levels and impaired glucose tolerance upon HFD feeding, relative to WT counterparts. Analysis of energy expenditure revealed that HFD-fed Ogg1−/− mice have a higher resting VCO2 and consequently, an increased respiratory quotient during the resting phase, indicating a preference for carbohydrate metabolism over fat oxidation in these mice. Additionally, microarray and quantitative PCR analyses revealed that key genes of fatty acid oxidation, including carnitine palmitoyl transferase-1, and the integral transcriptional co-activator Pgc-1α were significantly downregulated in Ogg1−/− livers. Multiple genes involved in TCA cycle metabolism were also significantly reduced in livers of Ogg1−/− mice. Furthermore, hepatic glycogen stores were diminished, and fasting plasma ketones were significantly reduced in Ogg1−/− mice. Collectively, these data indicate that OGG1 deficiency alters cellular substrate metabolism, favoring a fat sparing phenotype, that results in increased susceptibility to obesity and related pathologies in Ogg1−/− mice.


If left unrepaired, oxidative damage to DNA from exogenous oxidants, as well as endogenous metabolic byproducts, can lead to cellular transformation and ultimately to the development of tumors. Non-bulky oxidative DNA lesions are mainly repaired via the base-excision repair (BER) pathway [1][3], which is initiated by DNA glycosylases, such as 8-oxoguanine DNA glycosylase (OGG1), Nei endonuclease VIII-like (NEIL)1, NEIL2, NEIL3, and endonuclease III-like 1 (NTH1). These enzymes recognize and excise specific subsets of lesions, and in some cases, further process the damaged site to a single-strand break via their intrinsic apurinic/apyrimidinic lyase activity [2][4].

7,8-dihydro-8-oxoguanine (8-oxoG) is one of the most commonly formed oxidative lesions in the cell. Since it mispairs with A during replication, 8-oxoG is also a highly mutagenic lesion, producing G:C to T:A transversions. OGG1, a DNA repair glycosylase that localizes to both the nucleus and mitochondria, is the main enzyme responsible for identification and excision of 8-oxoG lesions [5][9]. OGG1 is hypothesized to play a role in several disease pathways, including various cancers [4], [10][16], neurological diseases such as Parkinson’s [17][19] and Alzheimers’ [20][24] disease, and aging-related pathologies [25][28]. A common link between these pathologies is the presence of elevated levels of oxidative stress. Another disease state that is associated with increased levels of oxidative stress is that of metabolic syndrome, which encompasses several pathologies, including increased body weight and adiposity, fatty liver, elevated triglycerides, and impaired glucose tolerance.

While it is generally postulated that oxidative stress leads to progression of disease, the molecular mechanisms that mediate this process are as yet largely unknown. Since oxidative stress can lead to damage of cellular components, including DNA, we hypothesized that the absence of a critical DNA repair protein, such as in the case of OGG1-deficient mice, would lower the cellular tolerance for oxidative stress, such as that induced by consumption of a high-fat diet. We have therefore investigated the role of OGG1 in the development of metabolic disease and report here a novel role for OGG1 in the maintenance of cellular and whole body energy balance.

Experimental Procedures

Animal Studies

The generation of Ogg1−/− mice backcrossed 21 times to C57BL/6J background has been previously described [15]. At OHSU, the Ogg1−/− allele was maintained through additional backcrossing to C57BL/6J and subsequent matings between Ogg1+/− mice. Age-matched male mice were exclusively used throughout this investigation. Six mice of each genotype were assigned to either chow diet or high-fat diet (HFD); this number was deemed to be the minimum required for adequate statistical power for the desired analyses based on our previous studies and similar reports in the literature. The breeding and care of animals are in accordance with the protocols approved by the Animal Care and Use Committee of Oregon Health & Science University, Portland, Oregon (Protocol Number A967). Prior to euthanasia by cervical dislocation, mice were anesthetized by CO2 inhalation. For in vivo procedures, all efforts were made to minimize discomfort and suffering, in accordance with approved animal care protocols.?For the diet studies, 12-week old mice were individually housed and given ad libitum access to either rodent chow or a HFD (Research Diets D12492, New Brunswick, NJ; 60% fat, 20% protein, 20% carbohydrate by calories; 5.24 kcal/g metabolizable energy) for 10 weeks. Food intake and body weights were measured weekly during this period. Body composition was measured by low-resolution NMR (Echo Medical Systems, Houston, TX) prior to and 4 weeks after the start of the feeding study.

Energy Expenditure

Energy expenditure was measured by indirect calorimetry (Oxymax, Columbus Instruments, Columbus, OH) as previously described [29], after 4 weeks of feeding. Briefly, oxygen consumption (VO2) and carbon dioxide production (VCO2) were simultaneously determined in individually housed animals with ad libitum access to chow or HFD and water. Following a 48-hour acclimation period, VO2 and VCO2 were recorded for 24 hours, including a 12-hour dark and 12-hour light phase. Samples were recorded every 2 minutes with a room air reference taken every 12 minutes. Respiratory exchange ratio (RER) was calculated as the molar ratio of VCO2: VO2.

Glucose, Insulin, and Glycogen Measurements

Glucose tolerance was assessed 7 weeks after the start of the study and was carried out as previously described [29]. Briefly, mice were fasted for 4 hours followed by i.p. injection of 10% dextrose at a rate of 1g/kg body weight. Blood was collected at the indicated intervals for assessment of plasma glucose using the glucose color reagent (Cliniqa, San Marcos, CA). Fasting plasma insulin was measured by ELISA (Millipore, St. Charles, MO). Hepatic glycogen was measured by an enzyme coupled spectrophotometric assay, as previously described [29].

Tissue Collection and Pathology

At the end of 10 weeks of feeding, mice were euthanized by CO2 overdose, and tissues were collected and snap frozen in liquid nitrogen for further analyses. For histological studies, liver and adipose tissues were fixed in buffered formalin and embedded in paraffin for sectioning and H&E staining. For transmission electron microscopy analyses, fresh liver sections were fixed and submitted to the Electron Microscopy Core at OHSU for sectioning and visualization. Buffer details are presented in Supplemental Methods.

Tissue and Plasma Lipids

Total hepatic triglycerides (TG) were analyzed using the Wako total TG kit (Wako Chemicals, Richmond, VA). For fasting plasma ketone analyses, age-matched mice were fasted overnight, and blood was collected via saphenous vein puncture. Plasma ketones were measured using the plasma β-hydroxybutyrate kit (Cayman Chemical Co., Ann Arbor, MI).

Physical Activity

Voluntary physical activity was assessed in chow-fed 12-week old male mice, as previously described [30]. Briefly, mice were acclimated to individual housing in shoebox cages equipped with running wheels for 7 days, and voluntary wheel running was measured for 2 consecutive weeks. Activity was monitored automatically using a Mini Mitter Magnetic Switch and the VitalView Data Acquisition System (Mini Mitter, Sun River, OR).

Mitochondrial DNA Quantitation and Gene Expression Analysis

Mitochondrial DNA content was measured as previously described [29]. DNA microarray experiments were conducted at the Affymetrix Microarray Core of the OHSU Gene Microarray Shared Resource. Gene expression was measured using the Mouse Gene ST GeneChip Array (Affymetrix, Inc., Santa Clara, Calif, Data visualization and exploratory analysis were conducted using GeneSifter web-based software, release 59.0 (GeoSpiza Inc., Seattle, WA). Analysis, quality control, and statistical methods are presented in Supplemental Methods. All microarray data has been deposited in GEO and may be accessed via accession number GSE35497. RNA for quantitative real-time PCR (qPCR) was isolated using Tri-reagent RT (MRC, Inc., Cincinnati, OH). 1 µg of RNA was reverse-transcribed using the Superscript III first-strand synthesis system (Invitrogen, Carlsbad, CA). qPCR was performed on a Bio-Rad iCycler qPCR instrument (Bio-Rad, Hercules, CA) using gene-specific primers. Gene expression was normalized to expression of 18S rRNA. Primer sequences are available upon request.

Statistical Analyses

Data are expressed as mean±SEM with comparisons carried out using student’s t-test for two-group comparisons (Figure 1C) or one-way ANOVA followed by post-hoc analysis using a multiple comparison procedure with Bonferroni/Dunn post-hoc comparison in Graphpad Prism. p-values <0.05 were considered significant.

Figure 1
Body weight, body composition, voluntary activity, and gene expression of BER glycosylases.


Ogg1−/− mice have an Increased Propensity to Adiposity, Especially Upon High-fat Diet Feeding

In a previous study examining potassium bromate-induced carcinogenesis in Ogg1−/− mice, data were also presented that suggested a trend towards increased body weights in Ogg1−/− mice, relative to wild-type (WT) counterparts that were maintained on a chow diet [31]. In order to determine if body weights and body composition are indeed significantly altered in Ogg1−/− animals, male mice were individually housed at 12 weeks of age and given ad libitum access to either chow or a hypercaloric high-fat diet (HFD). Over the duration of the 10-week study, chow-fed WT and Ogg1−/− mice displayed similar body weights (Figure 1A). HFD-feeding significantly increased weight gain in all mice, with WT mice gaining 17.5 g on average and Ogg1−/− counterparts gaining 20.4 g over 10 weeks of feeding (Figure 1A). However, total weight gain over the 10-week feeding period was not significantly different between WT and Ogg1−/− mice on either chow or HFD (Figure 1A). Although chow-fed Ogg1−/− mice were not significantly heavier at the end of the feeding study, in a separate cohort of animals allowed to age to 12–15 months on a chow diet, Ogg1−/− mice weighed 45.1±1.40 g (n = 5) on average, compared to WT counterparts that weighed 34.5±0.87 g (n = 6; p<0.05).

In addition to body weight, body composition was also measured by NMR before and 4 weeks after the start of feeding. Fat accumulation was significantly higher in HFD-fed Ogg1−/− mice, compared to WT counterparts (Figure 1B). While WT mice gained 9.14 g of fat (a 23% increase) upon HFD-feeding, Ogg1−/− mice gained 12.95 g of fat (a 28% increase) in the same period (Figure 1B). By 12–15 months of age, body fat in the aged cohort maintained on chow diet was also significantly different, with aged Ogg1−/− animals having 32.2% of their body weight as fat mass, compared to 19.5% body fat in WT counterparts (p<0.05). These data indicate that Ogg1−/− mice have an increased propensity to adiposity with age or in response to HFD-feeding, compared to WT controls.

At the end of the feeding period, visceral and subcutaneous adipose depots were collected and weighed. Both visceral (2.66±0.12 in WT vs. 2.91±0.19 g in Ogg1−/−; p>0.05) and subcutaneous (0.92±0.09 in WT vs. 1.28±0.06 g in Ogg1−/−; p<0.05 ) adipose depots tended to be larger in HFD-fed Ogg1−/− mice, relative to WT counterparts, indicating a generalized increase in fat accumulation in these mice. Voluntary activity (Figure 1C) and food intake were not significantly different between WT and Ogg1−/− mice either on chow (4.14±0.19 g in WT vs. 4.10±0.18 g in Ogg1−/−) or HFD (2.91±0.15 g in WT vs. 3.21±0.19 g in Ogg1−/−).

While a HFD is known to induce oxidative stress, the effect of extended high-fat feeding on expression of BER glycosylases has not been characterized. Therefore, we measured the expression of three key BER glycosylases, Ogg1, Neil1, and Nth1, in livers of chow- and HFD-fed mice (Figure 1D). HFD-feeding increased expression of all three glycosylases in WT mice, suggesting that the BER pathway is upregulated in response to HFD-feeding. Neil1 and Nth1 expression were increased by HFD-feeding in Ogg1−/− mice, as well. As expected, Ogg1 expression was undetectable in Ogg1−/− animals.

Ogg1−/− mice have Increased Hepatic Lipid Accumulation and Impaired Glucose Tolerance

Hepatic lipid accumulation was visualized by H&E staining, and total hepatic TG was quantified. Under chow-fed conditions, there were no significant differences in hepatic TG levels between WT and Ogg1−/− mice (Figures 2A, B). However, HFD-fed Ogg1−/− mice had a more than 2-fold higher accumulation of hepatic TG, compared to WT animals (Figures 2A, B).

Figure 2
Hepatic lipid accumulation and triglyceride content.

Since increased adiposity and hepatic lipid accumulation are risk factors for insulin resistance, glucose tolerance was assessed after 7 weeks of chow or HFD-feeding. After an intraperitoneal injection of glucose, chow-fed mice showed an increase in plasma glucose that returned to baseline levels by 180 minutes after injection (Figure 3A). As anticipated, HFD-feeding resulted in greater elevations in plasma glucose after glucose injection. While starting plasma glucose levels were comparable to WT values in HFD-fed Ogg1−/− mice, glucose clearance was significantly delayed in these animals. Plasma glucose levels at 90 and 180 minutes after glucose injection were significantly higher in HFD-fed Ogg1−/− mice, relative to WT counterparts (Figure 3A). Fasting plasma insulin levels were comparable in chow-fed WT and Ogg1−/− mice (Figure 3B). HFD-feeding increased fasting plasma insulin levels by 2.2-fold in WT mice and by 5.8-fold in Ogg1−/− animals (Figure 3B). In conjunction with the delayed glucose clearance (Figure 3A), the elevated plasma insulin levels in HFD-fed Ogg1−/− mice (Figure 3B) indicate a significant impairment in insulin sensitivity in these animals, relative to WT controls.

Figure 3
Glucose tolerance and plasma insulin.

Resting Respiratory Exchange Ratio, Fasting Plasma Ketones, and Hepatic Glycogen Content are Altered in Ogg1−/− mice

In order to determine if basal metabolic rates were altered due to OGG1 deficiency, O2 consumption and CO2 production were measured in chow and HFD-fed mice. There were no significant differences in O2 consumption or CO2 production between chow-fed WT and Ogg1−/− mice (Figures 4A and 4B). After HFD-feeding, CO2 production during the resting phase was significantly higher in Ogg1−/− mice, relative to WT animals (Figure 4C and 4D). Consistently, the respiratory exchange ratio (RER), an indicator of substrate utilization, was also significantly increased during the resting phase in HFD-fed Ogg1−/− mice (Figure 4F), relative to WT animals, indicating a slight, but significant decrease in reliance on fatty acid oxidation for energy needs during the resting phase in these animals.

Figure 4
Indirect calorimetry, plasma ketones, and hepatic glycogen.

Fasting plasma ketones were measured after an overnight fast to obtain an additional measure of in vivo fatty acid oxidation. Interestingly, in chow-fed Ogg1−/− mice, fasting plasma ketones were reduced by 39% (p<0.05), relative to WT controls (Figure 4G). HFD-fed Ogg1−/− mice also had a similar 34% decrease (p<0.05) in fasting plasma ketones, indicating reduced rates of fatty acid oxidation in Ogg1−/− mice.

Based on the significant increase in RER (Figure 4F), we hypothesized that Ogg1−/− mice may preferentially utilize carbohydrate stores to meet energy needs. Therefore, hepatic glycogen content was measured and found to be diminished by 27% (p<0.05) in both chow-fed and HFD-fed Ogg1−/− mice, relative to WT counterparts (Figure 4H). Concomitantly, we also observed a slight, but significant increase in gene expression of two rate-limiting glycolytic enzymes, glucokinase (32%; p<0.05) and phosphofructokinase (23%; p<0.05), in livers of HFD-fed Ogg1−/− mice. Taken together with the reduced fasting plasma ketones and the significant increase in resting phase RER, these data are suggestive of a decreased reliance on fatty acids as a fuel source in Ogg1−/− mice.

Since OGG1 has both nuclear and mitochondrial localization, we sought to determine if mtDNA content or mitochondrial structure was altered in Ogg1−/− mice. mtDNA abundance was measured by PCR and was not consistently reduced in all Ogg1−/− mice (Supporting Figure S1A). TEM analysis of mitochondrial density and ultrastructure in liver did not reveal differences between WT and Ogg1−/− mice (Supporting Figure S1B).

Hepatic Lipogenic Genes are not Upregulated in Ogg1−/− Livers

To gain further insight into the mechanistic changes underlying the metabolic phenotype of Ogg1−/− animals, hepatic gene expression was assessed through a combination of high-throughput DNA microarray and quantitative real-time PCR (qPCR). Analysis of differentially expressed probe sets (DEPs) by GeneSifter revealed 26 probesets (10 upregulated, 16 downregulated) to be altered by at least 1.5 fold in chow-fed Ogg1−/− livers, compared to WT livers (Supporting Table S1). After 10 weeks of HFD feeding, 1572 probesets were differentially expressed (132 upregulated and 1440 downregulated) in Ogg1−/− livers, compared to WT counterparts (Supporting Table S2). In addition to data analysis by GeneSifter, the Affymetrix data was simultaneously submitted to Ingenuity Systems for analysis via Ingenuity iReport for Gene Expression Analysis, the results of which were over 75% concordant with the GeneSifter analyses (Supporting Tables S3, S4). To investigate possible biological interactions and commonalities between the differentially regulated genes, DEPs identified by GeneSifter analyses were analyzed using Kyoto Encyclopedia of Genes and Genomes (KEGG) and gene ontology terms in GeneSifter, and pathways with a z-score greater than or equal to 2.0 and less than or equal to −2.0 were considered to be enriched or underrepresented, respectively (Supporting Tables S5, S6).

Given the observations of metabolic dysfunction in Ogg1−/− mice, the microarray data were queried for potential mechanisms that may explain these phenotypes. Since increased hepatic TG can occur secondary to increased de novo lipogenesis, we sought to determine if hepatic lipogenic genes were differentially regulated in livers of Ogg1−/− mice. The master regulator of lipogenic genes, sterol regulatory element binding protein-1c (SREBP-1c, gene ID: Srebf), which also regulates its own gene expression, was increased by 1.9-fold in livers of HFD-fed Ogg1−/− mice (Supporting Tables S2, S4). Interestingly, none of the classical target genes of SREBP-1c, including acetyl-CoA carboxylase (Acc), fatty acid synthase (Fas) or stearoyl-CoA desaturase-1 (Scd1) were found to be upregulated by either microarray or by qPCR analyses (Figure 5A). In fact, all these genes were significantly lower in livers of HFD-fed Ogg1−/− mice, relative to WT counterparts. The expression of PPAR gamma co-activator -1β (Pgc-1β), a requisite co-activator of SREBP-1c, was also significantly lower in HFD-fed Ogg1−/− mice, relative to WT mice (Figure 5A). This downregulation of Pgc1-β may explain the lack of increase in hepatic lipogenic gene expression, despite a significant induction of Srebp-1c. Nevertheless, based on these results, the increase in hepatic lipids in Ogg1−/− mice (Figure 2A) does not appear to be a consequence of increased hepatic lipogenesis.

Figure 5
Hepatic lipogenic and fatty acid oxidation gene expression.

Fatty Acid Oxidation and TCA Cycle Gene Expression is Reduced in Ogg1−/− Livers

Since resting phase RER was significantly higher and plasma ketones were reduced in HFD-fed Ogg1−/− mice, expression of genes involved in fat oxidation was examined. Consistent with a reduction in fatty acid oxidation, the microarray data revealed that several genes involved in fatty acid oxidation were significantly downregulated in HFD-fed Ogg1−/− livers, relative to WT counterparts (Table 1). Calcium-binding protein 39-like (Cab39l; also termed mouse protein 25 beta), electron-transferring-flavoprotein dehydrogenase (Etfdh), long-chain acyl-coenzymeA (CoA) synthetase isoforms 5 (Acsl5), AMP-activated protein kinase alpha subunit 2 (AMPKα2), PPAR-gamma coactivator -1 alpha (Pgc-1α), medium chain acyl-Coenzyme A dehydrogenase (Acadm), and peroxisomal enoyl-CoA delta isomerase (Peci), were all significantly downregulated by at least 1.5-fold in HFD-fed Ogg1−/− livers (Table 1). Furthermore, Pgc-1α, a key regulator of fatty acid oxidation gene expression in liver, was significantly lower in livers of chow-fed (Figure 5B), as well as HFD-fed (Table 1 and Figure 5B) Ogg1−/− mice. Concomitant with the reduction in Pgc-1α, additional key genes of fatty acid oxidation, including carnitine palmitoyl transferase-1 (Cpt-1), acyl CoA oxidase (Aox), and peroxisome proliferator-activated receptor alpha (Pparα)? were also decreased in HFD-fed Ogg1−/− mice, relative to WT counterparts (Figure 5B).

Table 1
Fatty acid oxidation genes.

In addition to fatty acid oxidation, PGC-1α also regulates genes involved in TCA cycle metabolism [32]. Consistent with the reduction in Pgc-1α levels (Table 1 and Figure 5B), several genes involved in the TCA cycle, including dihydrolipoamide dehydrogenase (Dld), malate dehydrogenase 1 (Mdh1), and fumarate hydratase (Fh) were all reduced by at least 1.5 fold in HFD-fed Ogg1−/− mice, as indicated by microarray analysis (Table 2). Additional genes involved in TCA cycle metabolism including isocitrate dehydrogenase 3 (Idh3a), pyruvate dehydrogenase E1 alpha 1 (Pdha1), succinate-Coenzyme A ligase (Sucla2), aconitase 1 (Aco1), succinate dehydrogenase complex, subunit A (Sdha) were all downregulated by at least 20% in HFD-fed Ogg1−/− livers (Table 2).

Table 2
TCA cycle metabolism genes.


We demonstrate here that the DNA repair glycosylase, OGG1, plays a novel role in regulating cellular energy metabolism. Ogg1 expression is induced in response to a HFD (Figure 1D), suggesting that the repair of oxidative lesions such as 8-oxo-G by OGG1 are part of the cellular response to oxidative stress, such as that induced by a HFD. Conversely, in the absence of OGG1, a HFD led to accelerated development of several features of metabolic syndrome, including increased adiposity (Figure 1B), hepatic lipid accumulation (Figure 2), and impaired glucose tolerance upon high-fat feeding (Figure 3A). This was accompanied by increased resting RER (Figure 4F), reduced fasting plasma ketones (Figure 4G), and reduced expression of key genes of fat oxidation (Table 1 and Figure 5B), all indicating a shift in energy metabolism in Ogg1−/− mice away from fat oxidation. Taken together with the reduced hepatic glycogen content in Ogg1−/− livers (Figure 4H), these changes are indicative of a shift in cellular metabolism towards glucose utilization, over fat oxidation, in Ogg1−/− livers.

Regulation of Pgc-1 Transcriptional Co-activators and Fatty Acid Oxidation in Response to DNA Damage

A striking observation in Ogg1−/− mice was that of reduced levels of both Pgc-1α and -1β expression in liver. These two highly regulated transcriptional co-activators play critical roles in diverse cellular processes [33][35]. PGC-1β is a requisite co-activator for the lipogenic transcription factor, SREBP-1c [36]. Therefore, the reduction in Pgc-1β levels (Figure 5A) in Ogg1−/− livers may explain the lack of induction of de novo lipogenesis in Ogg1−/− mice, despite a significant increase in Srebp-1c message levels (Figure 5A).

PGC-1α plays tissue-specific roles in pathways ranging from mitochondrial biogenesis [35] to TCA cycle flux [32] and fatty acid oxidation [33]. Chow-fed and HFD-fed Ogg1−/− mice had significantly reduced expression of hepatic Pgc-1α, compared to WT counterparts. Consistently, while expression of Cpt-1, a Pgc-1α target gene, was significantly elevated in response to HFD-feeding in WT mice (Figure 5B), Ogg1−/− animals did not show a similar induction of Cpt-1. Furthermore, several additional genes of fatty acid oxidation were found to be reduced, especially after HFD-feeding, in Ogg1−/− mice (Table 1 and Figure 5B). In addition to these changes in gene expression, Ogg1−/− mice also had significantly reduced plasma ketone levels following an overnight fast (Figure 4G), suggesting decreased fatty acid oxidation, consistent with the observation of elevated resting phase RER (Figure 4F) in these mice.

The observation of reduced levels of Pgc-1α in Ogg1−/− mice after HFD is especially striking. PGC-1α has been demonstrated to be downregulated in response to DNA damage via both reduced transcription of the gene [37], as well as through increased protein degradation [3]. Furthermore, several groups have reported a decrease in Pgc-1α levels in breast and colon cancers [38][40]. Given the role of OGG1 in maintaining genomic integrity, it is therefore plausible that the reduction of Pgc-1α upon HFD-feeding is directly or indirectly related to the DNA repair functionality of OGG1, and that this downregulation of Pgc-1α mediates the metabolic phenotype observed in Ogg1−/− mice. Additional studies are underway in order to understand the precise nature of the downregulation of Pgc-1α in Ogg1−/− mice, including regulation of the PGC-1α protein. However, from the current study, it is clear that OGG1 deficiency alters the hepatic response to a HFD such that expression of Pgc-1α, as well as that of several of its key downstream target genes, is blunted in Ogg1−/− mice. To our knowledge, this is the first demonstration of a DNA repair protein being directly linked to the dietary regulation of Pgc-1α and as such, provides important potentially mechanistic information regarding the pathology of diet-induced metabolic disease.

OGG1 Deficiency is Correlated with Human Metabolic Disease

In further support for a role for OGG1 in metabolic dysfunction, the Ser326Cys OGG1 polymorphism has been recently reported to be associated with Type II diabetes in both a Japanese and Mexican American population [41], [42]. While most studies investigating the consequences of human OGG1 polymorphisms have thus far been focused on the role of OGG1 in carcinogenesis, in light of the emerging evidence suggesting a role for OGG1 in maintaining energy balance, it will be interesting to determine if these common polymorphisms of human OGG1 are also associated with features of the metabolic syndrome. To our knowledge, studies investigating common gene polymorphisms and their correlations with increased body mass index have not thus far focused extensively on a role for DNA repair glycosylases such as Ogg1 or Neil1. Given the emerging link between these glycosylases and metabolic syndrome, a retrospective screen of specimens collected in previous studies may help shed light on potential correlations between inactivating mutations in Ogg1 and metabolic disease. In this regard, ongoing studies in our lab are aimed at characterizing the prevalence of common polymorphisms in the Ogg1 gene, as well as the extent of tissue DNA damage in cohorts such as individuals undergoing bariatric surgery to determine the incidence of inactivating mutations in DNA repair genes in obese populations.

OGG1 Acts through a Distinct Mechanism in Regulating Metabolic Parameters

We previously described a phenotype of spontaneous obesity and metabolic dysfunction in mice deficient in another BER glycosylase, NEIL1 [29], [43]. Neil1−/− mice spontaneously develop obesity on a chow diet, a phenotype that is greatly accelerated by HFD-feeding [29], [43]. This is accompanied by increased hepatic lipid accumulation and impairments in glucose tolerance in Neil1−/− mice [29], [43]. Since NEIL1 and OGG1 have very distinct substrate specificities in the repair of oxidized lesions, these similarities in phenotype with regard to the development of metabolic syndrome were completely unexpected. Indeed, a similar phenotype has not been observed in mice deficient in NEIL3 [44], despite considerable overlap in substrate specificities between NEIL1 and NEIL3. Interestingly, despite broad similarities in phenotype between Neil1−/− and Ogg1−/− mice, these two models exhibit important differences in the mechanisms underlying the observed pathologies. While overall energy expenditure was reduced in Neil1−/− mice [29], we did not observe any specific changes in RER [29] or fasting ketones in Neil1−/− animals (Sampath, Lloyd; unpublished), suggesting a generalized decrease in metabolic rate in Neil1−/− mice, rather than altered substrate preference, as observed in Ogg1−/− animals (Figures 4D,F). Furthermore, gene expression analysis of livers of Neil1−/− mice revealed a marked increase in inflammatory gene expression [29], while such a phenotype was not evident in the Ogg1−/− mice in the current study. This lack of an inflammatory response in Ogg1−/− livers, despite increased lipid accumulation, is consistent with other reports of an attenuated inflammatory response in the absence of OGG1 [45], [46], suggesting a possible role for excision of 8-oxoG and its subsequent release into the circulation in modulating the tissue inflammatory response.

Based on the results of the current study, we propose that oxidative stress, such as that resulting from HFD-feeding, results in DNA damage and a compensatory upregulation of the BER pathway to address this damage (Figures 1D, ,6).6). In the absence of OGG1, a critical enzyme of the BER system, DNA damage goes unrepaired, leading to an aberrant response to a HFD in terms of regulation of Pgc-1α expression and fatty acid oxidation (Figures 4D, 4F, 4G, ,5B,5B, ,6).6). Misregulation of these mediators leads to sparing of fat as a fuel and ultimately to lipid accumulation and obesity in Ogg1−/− mice (Figures 1B, ,2,2, ,6).6). These findings shed light on a novel pathway of metabolic regulation downstream of DNA damage and argue for an unexpected but critical role for OGG1 and the BER pathway in the maintenance of whole body energy balance.

Figure 6
Proposed model for maintenance of metabolic health by OGG1.

Supporting Information

Figure S1

Mitochondrial DNA content and mitochondrial ultrastructure. Mitochondrial DNA content (A, B) was measured by PCR using primers directed against two different regions of mitochondrial DNA. n = 5–6 in each group. CytoxII, cytochrome c oxidase, subunit 2; ND5, NADH dehydrogenase subunit 5. Mitochondrial density and ultrastructure in liver was also visualized by TEM (C). Images are representative of 3 animals per group. Scale bar represents 8.33 µM in all images.


Table S1

Differentially expressed probesets (DEPs) identified by GeneSifter in chow-fed Ogg1−/− livers. Pairwise analysis of chow-fed WT vs. Ogg1−/− was performed by t-test between the groups, followed by a Benjamini and Hochberg adjustment used to correct for false discovery rates using GeneSifter software. WT mice were designated as the control group, and Ogg1−/− mice were designated as the experimental group. Probesets that were differentially expressed by at least 1.5 fold and with an adjusted p<0.05 are presented. n = 6 in each group.


Table S2

DEPs identified by GeneSifter in HFD-fed Ogg1−/− livers. Pairwise analysis of HFD-fed WT vs. Ogg1−/− was performed by t-test between the groups, followed by a Benjamini and Hochberg adjustment used to correct for false discovery rates using GeneSifter software. WT mice were designated as the control group, and Ogg1−/− mice were designated as the experimental group. Probesets that were differentially expressed by at least 1.5 fold and with an adjusted p<0.05 are presented. n = 6 in each group.


Table S3

DEPs identified by iReport in chow-fed Ogg1−/− livers. Pairwise analysis of chow-fed WT vs. Ogg1−/− was conducted by iReport (Ingenuity Systems, Redwood City, CA), with WT mice were designated as the control group, and Ogg1−/− mice designated as the experimental group. Probesets that were differentially expressed by at least 1.5 fold and with an adjusted p<0.05 are presented. n = 6 in each group.


Table S4

DEPs identified by iReport in HFD-fed Ogg1−/− livers. Pairwise analysis of HFD-fed WT vs. Ogg1−/was conducted by iReport (Ingenuity Systems, Redwood City, CA), with WT mice were designated as the control group, and Ogg1−/− mice designated as the experimental group. Probesets that were differentially expressed by at least 1.5 fold and with an adjusted p<0.05 are presented. n = 6 in each group.


Table S5

KEGG Pathway analysis of DEPs in chow-fed Ogg1−/− livers. DEPs that were altered by at least 1.4 fold in chow-fed Ogg1−/− livers, relative to WT livers, were annotated using the Kyoto Encyclopedia of Genes and Genomes (KEGG) in GeneSifter. All pathways with an associated z-score >2.0 or <−2.0 are presented. n = 6 per group. n = 6 in each group.


Table S6

KEGG Pathway analysis of DEPs in HFD-fed Ogg1−/− livers. DEPs that were altered by at least 1.4 fold in HFD-fed Ogg1−/− livers, relative to WT livers, were annotated using the Kyoto Encyclopedia of Genes and Genomes (KEGG) in GeneSifter. All pathways with an associated z-score >2.0 or <−2.0 are presented. n = 6 per group.


Methods S1

Supporting Methods.



We would like to thank Drs. Daniel Marks and Lisa Wood (OHSU, Portland, OR) for the use of small animal MRI and indirect calorimetry chambers, and wheel running cages, respectively; Dr. Peter Spencer (OHSU) for interpretation of TEM images; and Drs. James Ntambi (UW-Madison) and Amanda McCullough (OHSU) for valuable discussions.

Funding Statement

This work was supported by American Heart Association Postdoctoral grant 11POST7480004 (HS) and National Institutes of Health (NIH) R01 DK075974 (RSL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Nemec AA, Wallace SS, Sweasy JB (2010) Variant base excision repair proteins: contributors to genomic instability. Semin Cancer Biol 20: 320–328. [PMC free article] [PubMed]
2. Hazra TK, Das A, Das S, Choudhury S, Kow YW, et al. (2007) Oxidative DNA damage repair in mammalian cells: a new perspective. DNA Repair (Amst) 6: 470–480. [PMC free article] [PubMed]
3. Kim HJ, Jee HJ, Yun J (2011) DNA damage induces down-regulation of PEPCK and G6P gene expression through degradation of PGC-1alpha. Acta Biochim Biophys Sin (Shanghai) 43: 589–594. [PubMed]
4. Sampath H, McCullough AK, Lloyd RS (2012) Regulation of DNA glycosylases and their role in limiting disease. Free Radic Res 46: 460–478. [PubMed]
5. Klungland A, Bjelland S (2007) Oxidative damage to purines in DNA: role of mammalian Ogg1. DNA Repair (Amst) 6: 481–488. [PubMed]
6. Klungland A, Rosewell I, Hollenbach S, Larsen E, Daly G, et al. (1999) Accumulation of premutagenic DNA lesions in mice defective in removal of oxidative base damage. Proc Natl Acad Sci U S A 96: 13300–13305. [PubMed]
7. Nishioka K, Ohtsubo T, Oda H, Fujiwara T, Kang D, et al. (1999) Expression and differential intracellular localization of two major forms of human 8-oxoguanine DNA glycosylase encoded by alternatively spliced OGG1 mRNAs. Mol Biol Cell 10: 1637–1652. [PMC free article] [PubMed]
8. Radicella JP, Dherin C, Desmaze C, Fox MS, Boiteux S (1997) Cloning and characterization of hOGG1, a human homolog of the OGG1 gene of Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 94: 8010–8015. [PubMed]
9. Rosenquist TA, Zharkov DO, Grollman AP (1997) Cloning and characterization of a mammalian 8-oxoguanine DNA glycosylase. Proc Natl Acad Sci U S A 94: 7429–7434. [PubMed]
10. Paz-Elizur T, Sevilya Z, Leitner-Dagan Y, Elinger D, Roisman LC, et al. (2008) DNA repair of oxidative DNA damage in human carcinogenesis: potential application for cancer risk assessment and prevention. Cancer Lett 266: 60–72. [PMC free article] [PubMed]
11. Chevillard S, Radicella JP, Levalois C, Lebeau J, Poupon MF, et al. (1998) Mutations in OGG1, a gene involved in the repair of oxidative DNA damage, are found in human lung and kidney tumours [In Process Citation]. Oncogene 16: 3083–3086. [PubMed]
12. Lu R, Nash HM, Verdine GL (1997) A mammalian DNA repair enzyme that excises oxidatively damaged guanines maps to a locus frequently lost in lung cancer. Curr Biol 7: 397–407. [PubMed]
13. Michaels ML, Miller JH (1992) The GO system protects organisms from the mutagenic effect of the spontaneous lesion 8-hydroxyguanine (7,8-dihydro-8-oxoguanine). J Bacteriol 174: 6321–6325. [PMC free article] [PubMed]
14. Okasaka T, Matsuo K, Suzuki T, Ito H, Hosono S, et al. (2009) hOGG1 Ser326Cys polymorphism and risk of lung cancer by histological type. J Hum Genet 54: 739–745. [PubMed]
15. Sakumi K, Tominaga Y, Furuichi M, Xu P, Tsuzuki T, et al. (2003) Ogg1 knockout-associated lung tumorigenesis and its suppression by Mth1 gene disruption. Cancer Res 63: 902–905. [PubMed]
16. Thomas D, Scot AD, Barbey R, Padula M, Boiteux S (1997) Inactivation of OGG1 increases the incidence of G. C–>T. A transversions in Saccharomyces cerevisiae: evidence for endogenous oxidative damage to DNA in eukaryotic cells. Mol Gen Genet 254: 171–178. [PubMed]
17. Fukae J, Takanashi M, Kubo S, Nishioka K, Nakabeppu Y, et al. (2005) Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson’s disease and related neurodegenerative disorders. Acta Neuropathol 109: 256–262. [PubMed]
18. Nakabeppu Y, Tsuchimoto D, Yamaguchi H, Sakumi K (2007) Oxidative damage in nucleic acids and Parkinson’s disease. J Neurosci Res 85: 919–934. [PubMed]
19. Cardozo-Pelaez F, Cox DP, Bolin C (2005) Lack of the DNA repair enzyme OGG1 sensitizes dopamine neurons to manganese toxicity during development. Gene Expr 12: 315–323. [PubMed]
20. Dezor M, Dorszewska J, Florczak J, Kempisty B, Jaroszewska-Kolecka J, et al. (2011) Expression of 8-oxoguanine DNA glycosylase 1 (OGG1) and the level of p53 and TNF-alphalpha proteins in peripheral lymphocytes of patients with Alzheimer’s disease. Folia Neuropathol 49: 123–131. [PubMed]
21. Iida T, Furuta A, Nishioka K, Nakabeppu Y, Iwaki T (2002) Expression of 8-oxoguanine DNA glycosylase is reduced and associated with neurofibrillary tangles in Alzheimer’s disease brain. Acta Neuropathol 103: 20–25. [PubMed]
22. Dorszewska J, Kempisty B, Jaroszewska-Kolecka J, Rozycka A, Florczak J, et al. (2009) Expression and polymorphisms of gene 8-oxoguanine glycosylase 1 and the level of oxidative DNA damage in peripheral blood lymphocytes of patients with Alzheimer’s disease. DNA Cell Biol 28: 579–588. [PubMed]
23. Shao C, Xiong S, Li GM, Gu L, Mao G, et al. (2008) Altered 8-oxoguanine glycosylase in mild cognitive impairment and late-stage Alzheimer’s disease brain. Free Radic Biol Med 45: 813–819. [PMC free article] [PubMed]
24. Mao G, Pan X, Zhu BB, Zhang Y, Yuan F, et al. (2007) Identification and characterization of OGG1 mutations in patients with Alzheimer’s disease. Nucleic Acids Res 35: 2759–2766. [PMC free article] [PubMed]
25. Kaneko T, Tahara S, Matsuo M (1996) Non-linear accumulation of 8-hydroxy-2′-deoxyguanosine, a marker of oxidized DNA damage, during aging. Mutat Res 316: 277–285. [PubMed]
26. Radak Z, Boldogh I (2010) 8-Oxo-7,8-dihydroguanine: links to gene expression, aging, and defense against oxidative stress. Free Radic Biol Med 49: 587–596. [PMC free article] [PubMed]
27. Radak Z, Bori Z, Koltai E, Fatouros IG, Jamurtas AZ, et al. (2011) Age-dependent changes in 8-oxoguanine-DNA glycosylase activity are modulated by adaptive responses to physical exercise in human skeletal muscle. Free Radic Biol Med 51: 417–423. [PubMed]
28. Radak Z, Naito H, Kaneko T, Tahara S, Nakamoto H, et al. (2002) Exercise training decreases DNA damage and increases DNA repair and resistance against oxidative stress of proteins in aged rat skeletal muscle. Pflugers Arch 445: 273–278. [PubMed]
29. Sampath H, Batra AK, Vartanian V, Carmical JR, Prusak D, et al. (2011) Variable penetrance of metabolic phenotypes and development of high-fat diet-induced adiposity in NEIL1-deficient mice. Am J Physiol Endocrinol Metab 300: E724–734. [PubMed]
30. Wood LJ, Nail LM, Perrin NA, Elsea CR, Fischer A, et al. (2006) The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms. Biol Res Nurs 8: 157–169. [PubMed]
31. Arai T, Kelly VP, Minowa O, Noda T, Nishimura S (2006) The study using wild-type and Ogg1 knockout mice exposed to potassium bromate shows no tumor induction despite an extensive accumulation of 8-hydroxyguanine in kidney DNA. Toxicology 221: 179–186. [PubMed]
32. Burgess SC, Leone TC, Wende AR, Croce MA, Chen Z, et al. (2006) Diminished hepatic gluconeogenesis via defects in tricarboxylic acid cycle flux in peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha)-deficient mice. J Biol Chem 281: 19000–19008. [PMC free article] [PubMed]
33. Puigserver P (2005) Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha. Int J Obes (Lond) 29 Suppl 1S5–9. [PubMed]
34. Liu C, Lin JD (2011) PGC-1 coactivators in the control of energy metabolism. Acta Biochim Biophys Sin (Shanghai) 43: 248–257. [PMC free article] [PubMed]
35. Fernandez-Marcos PJ, Auwerx J (2011) Regulation of PGC-1alpha, a nodal regulator of mitochondrial biogenesis. Am J Clin Nutr 93: 884S–890. [PubMed]
36. Lin J, Yang R, Tarr PT, Wu PH, Handschin C, et al. (2005) Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell 120: 261–273. [PubMed]
37. Sahin E, Colla S, Liesa M, Moslehi J, Muller FL, et al. (2011) Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 470: 359–365. [PubMed]
38. Feilchenfeldt J, Brundler MA, Soravia C, Totsch M, Meier CA (2004) Peroxisome proliferator-activated receptors (PPARs) and associated transcription factors in colon cancer: reduced expression of PPARgamma-coactivator 1 (PGC-1). Cancer Lett 203: 25–33. [PubMed]
39. Watkins G, Douglas-Jones A, Mansel RE, Jiang WG (2004) The localisation and reduction of nuclear staining of PPARgamma and PGC-1 in human breast cancer. Oncol Rep 12: 483–488. [PubMed]
40. Jiang WG, Douglas-Jones A, Mansel RE (2003) Expression of peroxisome-proliferator activated receptor-gamma (PPARgamma) and the PPARgamma co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. Int J Cancer 106: 752–757. [PubMed]
41. Thameem F, Puppala S, Lehman DM, Stern MP, Blangero J, et al. (2010) The Ser(326)Cys Polymorphism of 8-Oxoguanine Glycosylase 1 (OGG1) Is Associated with Type 2 Diabetes in Mexican Americans. Hum Hered 70: 97–101. [PMC free article] [PubMed]
42. Daimon M, Oizumi T, Toriyama S, Karasawa S, Jimbu Y, et al. (2009) Association of the Ser326Cys polymorphism in the OGG1 gene with type 2 DM. Biochem Biophys Res Commun 386: 26–29. [PubMed]
43. Vartanian V, Lowell B, Minko IG, Wood TG, Ceci JD, et al. (2006) The metabolic syndrome resulting from a knockout of the NEIL1 DNA glycosylase. Proc Natl Acad Sci U S A 103: 1864–1869. [PubMed]
44. Torisu K, Tsuchimoto D, Ohnishi Y, Nakabeppu Y (2005) Hematopoietic tissue-specific expression of mouse Neil3 for endonuclease VIII-like protein. J Biochem 138: 763–772. [PubMed]
45. Li G, Yuan K, Yan C, Fox J 3rd, Gaid M, et al (2011) 8-Oxoguanine-DNA glycosylase 1 deficiency modifies allergic airway inflammation by regulating STAT6 and IL-4 in cells and in mice. Free Radic Biol Med 52: 392–401. [PubMed]
46. Casorelli I, Pannellini T, De Luca G, Degan P, Chiera F, et al. (2010) The Mutyh base excision repair gene influences the inflammatory response in a mouse model of ulcerative colitis. PLoS One 5: e12070. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science